Search

Displaying results 3091 - 3100 of 10000 in total
  1. Target

    E3 ubiquitin ligase TRAF3IP2

    go.drugbank.com/bio_entities/BE0011632
    TargetHumans

    Transfers ubiquitin from E2 ubiquitin-conjugating enzyme UBE2V1-UBE2N to substrate protein (PubMed:19825828). … Upon IL17A stimulation, interacts with IL17RA and IL17RC receptor chains through SEFIR domains and catalyzes 'Lys-63'-linked polyubiquitination of TRAF6, leading to TRAF6-mediated activation of NF-kappa-B

    Synonyms: Connection to IKK and SAPK/JNK
  2. Drug

    Sulfadimethoxine

    go.drugbank.com/drugs/DB06150
    ApprovedVet approvedWithdrawn

    Sulfadimethoxine is used to treat many infections, including treatment of respiratory, urinary tract, enteric, and soft tissue infections. … In the US, sulfadimethoxine is one of the products that have been withdrawn or removed from the market after being found to be unsafe or not effective.[L43942]

    Mixtures: TP-SULTRIXIN 40/200MG/ML SOLUTION, TP-SULTRIME 80/400MG/G POWDERCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  3. Drug

    XL784

    go.drugbank.com/drugs/DB04991
    Investigational

    XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation. … It is being developed by Exelixis, Inc.

  4. Indication

    Ovulation Absent

    go.drugbank.com/conditions/DBCOND0140456
    Drugs: Letrozole
    Synonyms: Female infertility due to anovulation (disorder)
  5. Drug

    Panobinostat

    go.drugbank.com/drugs/DB06603
    ApprovedInvestigational

    The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted … Panobinostat is marketed by Novartis under the brand name Farydak.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  6. Drug

    Oxantel

    go.drugbank.com/drugs/DB13670
    Investigational

    Oxantel is an anthelmintic drug that targets parasitic acetylcholine receptors.

    Mixtures: PAMOXPEN - PAMOATO DE PIRANTEL100 MG+ PAMOATO DE OXANTEL 100 MG TABLETAS, PAMOATO DE OXANTEL 250 MG/5ML + PAMOATO DE PIRANTEL 250 MG/5 ML SUSPENSIÓN.
  7. Drug

    Human vaccinia virus immune globulin

    go.drugbank.com/drugs/DB14112
    ApprovedInvestigational

    The IgG fraction is purified by the anion-exchange column chromatography method and the solution is solvent/detergent-treated to sterilize the compound [A33814]. … Nevertheless, VIG by virtue of the way it is produced is a poorly characterized and highly variable human product that is only available in very limited quantities - all factors that may intervene with

    Categories: Immunoglobulin G, Human Immunoglobulin G
  8. Drug

    Rutin

    go.drugbank.com/drugs/DB01698
    ApprovedInvestigational

    It has been used therapeutically to decrease capillary fragility.

    Mixtures: Nutriforte Non-Acidic Vitamin C 1000 mg with Bioflavonoids, NAT-C 1000Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 Inducers
  9. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    [A229273] Loss-of-function mutations in _ANGPTL3_ have been noted to result in hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with … [L31838] In September and December 2023, evinacumab was also approved by Health Canada and EMA, respectively, for the same indication.[L49956,L49966]

  10. Drug

    Benzyl nicotinate

    go.drugbank.com/drugs/DB15764
    Investigational

    Mixtures: HOTFİX 100 MG/G + 10 MG/G KREM , 50 GRAM, THERMO RHEUMON 100 MG/G + 10 MG/G KREM, 50 G